Pharmaniaga Stock

Equities

PHARMA

MYL7081OO002

Pharmaceuticals

End-of-day quote BURSA MALAYSIA 18:00:00 2024-06-17 EDT 5-day change 1st Jan Change
0.375 MYR +1.35% Intraday chart for Pharmaniaga -1.32% -2.60%

Financials

Sales 2024 * 3.51B 744M 1.02B Sales 2025 * 3.58B 759M 1.04B Capitalization 540M 115M 157M
Net income 2024 * 50M 10.61M 14.52M Net income 2025 * 48M 10.19M 13.94M EV / Sales 2024 * 0.15 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 0.15 x
P/E ratio 2024 *
10.7 x
P/E ratio 2025 *
11 x
Employees 3,476
Yield 2024 *
-
Yield 2025 *
-
Free-Float 41.76%
More Fundamentals * Assessed data
Dynamic Chart
Pharmaniaga Shareholders OK Renewal of Share Buyback, Transaction Mandates MT
Pharmaniaga Berhad Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Pharmaniaga Berhad Appoints Encik Mohd Firdaus Bin Zulkifli as Alternate Director and Non Independent and Non Executive CI
China's drugmakers can't sell mRNA shots but haven't quit yet RE
Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee CI
Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Nomination and Remuneration Committee CI
Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof as Independent and Non Executive Member of Risk Committee CI
Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof as Independent and Non Executive Member of Nomination and Remuneration Committee CI
Pharmaniaga Berhad Appoints Dato' Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Chairman of Risk Committee CI
Pharmaniaga Berhad Announces Redesignation of Puan Sarah Azreen Binti Abdul Samat from Chairman of Risk Committee to Member of Risk Committee CI
Pharmaniaga Berhad Appoints Dato' Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Member of Audit Committee CI
Pharmaniaga Berhad Announces the Retirement of Encik Mohamed Iqbal Abdul Rahman as Chief Operating Officer CI
Pharmaniaga Trims Loss in Q4 2024 MT
Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Director, Effective March 1, 2024 CI
Pharmaniaga Berhad Appoints Encik Zulkifli Bin Jafar as Executive Director, Effective March 1, 2024 CI
More news
1 day+1.35%
1 week+1.35%
Current month+4.17%
1 month+22.95%
3 months+4.17%
6 months-8.54%
Current year-2.60%
More quotes
1 week
0.37
Extreme 0.365
0.39
1 month
0.31
Extreme 0.305
0.41
Current year
0.30
Extreme 0.295
0.44
1 year
0.30
Extreme 0.295
0.51
3 years
0.22
Extreme 0.22
1.10
5 years
0.18
Extreme 0.182
1.45
10 years
0.18
Extreme 0.182
1.51
More quotes
Managers TitleAgeSince
Director of Finance/CFO 57 01-04-30
Chief Tech/Sci/R&D Officer 52 22-12-31
Chief Tech/Sci/R&D Officer 56 22-12-31
Members of the board TitleAgeSince
Chairman 55 22-11-29
Director/Board Member 52 20-08-02
Director/Board Member 49 -
More insiders
Date Price Change Volume
24-06-18 0.375 +1.35% 2,716,900
24-06-14 0.37 -2.63% 730,000
24-06-13 0.38 +2.70% 1,502,700
24-06-12 0.37 -2.63% 2,052,400
24-06-11 0.38 +2.70% 2,864,000

End-of-day quote BURSA MALAYSIA, June 17, 2024

More quotes
Pharmaniaga Berhad is an investment holding company. The Company is principally engaged in the research and development, manufacturing of generic drugs and medical devices, logistics and distribution, sales, and marketing, as well as community pharmacy. The Company operates through three segments: Logistics and distribution, Manufacturing, and Indonesia. The Logistics and distribution is engaged in the distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia. The Manufacturing segment is engaged in the manufacturing of pharmaceutical products in Malaysia. Indonesia segment is engaged in the manufacturing and distribution of pharmaceutical and medical products in Indonesia. The Company’s subsidiaries include Idaman Pharma Manufacturing Sdn. Bhd., Pharmaniaga Manufacturing Berhad, Pharmaniaga LifeScience Sdn. Bhd., Pharmaniaga Logistics Sdn. Bhd., and Pharmaniaga Marketing Sdn. Bhd.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
0.375 MYR
Average target price
0.34 MYR
Spread / Average Target
-9.33%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. PHARMA Stock